Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guofeng Cheng

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
Plos One|January 18, 2017
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after InfectionCongrong Niu, Christine M Livingston, Li Li, et al.
Signal Transduction and Targeted Therapy|August 30, 2022
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal deliveryXinghai Zhang, Huajun Zhang, Tingting Li, et al.
Research (Washington, D.C.)|September 6, 2024
Enhanced Effects of Intermittent Fasting by Magnetic Fields in Severe DiabetesYing Wang, Chuanlin Feng, Biao Yu, et al.
Journal of Virology|July 21, 2021
Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell LinesRicardo Ramirez, Nicholas van Buuren, Lindsay Gamelin, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirGuofeng Cheng, Yang Tian, Brian Doehle, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 8, 2022
Neurotoxicity of an Hepatitis B Virus (HBV) Transcript Inhibitor in 13-Week Rat and Monkey StudiesApril D Lake, Kevin Holsapple, Tanya McDonnell, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451Huiling Yang, Margaret Robinson, Amoreena C Corsa, et al.
Nature Communications|January 10, 2026
Decoupling slab gliding and lattice contraction in Na layered oxides to enable high-voltage Na-ion batteriesQinhao Shi, Fanghua Ning, Xuan Yu, et al.
Hepatology International|May 23, 2026
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b studyWen Wang, Jiajia Mai, Jinlin Hou, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Plos One|January 18, 2017
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after InfectionCongrong Niu, Christine M Livingston, Li Li, et al.
Signal Transduction and Targeted Therapy|August 30, 2022
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal deliveryXinghai Zhang, Huajun Zhang, Tingting Li, et al.
Research (Washington, D.C.)|September 6, 2024
Enhanced Effects of Intermittent Fasting by Magnetic Fields in Severe DiabetesYing Wang, Chuanlin Feng, Biao Yu, et al.
Journal of Virology|July 21, 2021
Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell LinesRicardo Ramirez, Nicholas van Buuren, Lindsay Gamelin, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirGuofeng Cheng, Yang Tian, Brian Doehle, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 8, 2022
Neurotoxicity of an Hepatitis B Virus (HBV) Transcript Inhibitor in 13-Week Rat and Monkey StudiesApril D Lake, Kevin Holsapple, Tanya McDonnell, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451Huiling Yang, Margaret Robinson, Amoreena C Corsa, et al.
Nature Communications|January 10, 2026
Decoupling slab gliding and lattice contraction in Na layered oxides to enable high-voltage Na-ion batteriesQinhao Shi, Fanghua Ning, Xuan Yu, et al.
Hepatology International|May 23, 2026
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b studyWen Wang, Jiajia Mai, Jinlin Hou, et al.
Journal of Medicinal Chemistry|August 17, 2016
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus InfectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Pageof 14